Regulation of CD4 T cell tolerance by the NR4A family of nuclear receptors

核受体 NR4A 家族对 CD4 T 细胞耐受性的调节

基本信息

项目摘要

Project Summary/Abstract This proposal’s long-term goal is to take advantage of the biology of the NR4A family of orphan nuclear hormone receptors to selectively manipulate antigen-specific T cell responses in immune-mediated diseases. NR4A members (NUR77, NURR1, and NOR1) are encoded by three genes (Nr4a1-3, respectively) that are rapidly induced by antigen (Ag) stimulation in lymphocytes. Although they are thought to function as ligand- independent, constitutively active transcription factors, small molecule agonist and antagonist ligands have been developed, rendering them druggable. We and others have shown that NR4A TF expression scales with the intensity of Ag stimulation, and are highly upregulated in thymocytes undergoing negative selection, in regulatory T cells (Tregs), as well as in self-reactive, anergic, or exhausted T cells. Due to an overlapping expression pattern and considerable structural homology in their DNA-binding domain, the NR4A TFs exhibit profound functional redundancy; thymic deletion of multiple - but not individual - NR4A family members (Nr4a1 and Nr4a3 >> Nr4a2, which is minimally expressed) results in severe Treg deficiency and a “scurfy-like” disease that phenocopies Foxp3-/- mice. Consequently, it has not been possible previously to unmask additional redundant functions of this family during thymic selection and in conventional mature CD4 T cells (Tconv). This represents a major gap in our knowledge that limits full therapeutic exploitation of these factors. Recently, we took advantage of both conditional genetic and bone marrow chimera strategies in order to preserve Treg homeostasis. Unexpectedly, mixed chimeras harboring both WT and Nr4a1-/- Nr4a3-/- (DKO) bone marrow rapidly develop anti-nuclear autoantibodies (ANAs) and a systemic inflammatory disease despite a replete Treg compartment of largely WT origin. This disease differs qualitatively from that seen in germline DKO mice with Treg-deficiency, and is B cell-extrinsic. We show that negative selection of DKO thymocytes is profoundly impaired in a cell-intrinsic manner. Consistent with escape of self-reactive T cells into the periphery, DKO CD4 Tconv cells expressing phenotypic and transcriptional markers of anergy accumulate in these chimeras. However, these self-reactive DKO cells nevertheless exhibit exaggerated proliferation and IL-2 production, suggesting that functional anergy is defective. We therefore hypothesize that the NR4A family play cell-intrinsic, but redundant, roles in both central and peripheral CD4 T cell tolerance. To test this hypothesis: In our first aim, we propose to define the role of the NR4A family in thymic negative selection in the face of both ubiquitous and tissue-restricted antigens, and to define the transcriptional targets that contribute to this function. In our second aim, we propose to isolate NR4A contributions to peripheral T cell tolerance, and to canonical features of mature CD4 T cell anergy - including impaired signal transduction, cytokine production, and proliferation. We will use both bulk and single cell genomic approaches to define the mechanism by which the NR4A family regulates the transcriptome and epigenetic profile of naïve and tolerant CD4 T cells.
项目总结/摘要 这项提案的长期目标是利用孤儿核激素NR 4A家族的生物学 受体,以选择性地操纵免疫介导的疾病中的抗原特异性T细胞应答。 NR 4A成员(NR 477、NR 4 R1和NOR 1)由三个基因(分别为Nr 4a 1 -3)编码, 在淋巴细胞中通过抗原(Ag)刺激快速诱导。尽管它们被认为是配体- 独立的、组成型活性转录因子、小分子激动剂和拮抗剂配体已经被 使它们变得可药用。我们和其他人已经表明,NR 4A TF表达与肿瘤大小成比例。 Ag刺激的强度,并在经历负选择的胸腺细胞中高度上调,在调节 T细胞(Tcells),以及自身反应性、无反应性或耗竭的T细胞。由于重叠的表达模式 和相当大的结构同源性,在它们的DNA结合域,NR 4A转录因子表现出深刻的功能 冗余;多个-而非单个-NR 4A家族成员的胸腺缺失(Nr 4a 1和Nr 4a 3>> Nr 4a 2, 最低限度表达)导致严重的Treg缺乏和表型模仿的“皮屑样”疾病 Foxp 3-/-小鼠。因此,先前不可能揭露附加的冗余功能, 在胸腺选择和常规成熟CD 4 T细胞(Tconv)中,这是一个重大差距 这限制了对这些因素的充分利用。 最近,我们利用了条件遗传和骨髓嵌合体策略,以保持 Treg稳态。出乎意料的是,携带WT和Nr 4a 1-/-Nr 4a 3-/-(DKO)骨髓的混合嵌合体 快速发展抗核自身抗体(ANA)和全身性炎症性疾病,尽管Treg 大部分WT起源的区室。这种疾病在性质上不同于在生殖系DKO小鼠中观察到的, Treg缺陷,并且是B细胞外源性的。我们发现,DKO胸腺细胞的负选择是深刻的, 以细胞内在的方式受损。与自身反应性T细胞逃逸到外周一致,DKO CD 4 表达无反应性表型和转录标记的Tconv细胞在这些嵌合体中积累。 然而,这些自身反应性DKO细胞仍然表现出过度的增殖和IL-2产生, 提示功能性无反应性是有缺陷的。因此,我们假设NR 4A家族发挥细胞内在作用, 但是多余的,在中枢和外周CD 4 T细胞耐受中的作用。为了检验这一假设: 在我们的第一个目标中,我们建议定义NR 4A家族在胸腺负选择中的作用, 普遍存在的和组织限制性的抗原,并确定有助于这一功能的转录靶点。 在我们的第二个目标中,我们建议分离NR 4A对外周T细胞耐受性的贡献,以及对典型的T细胞耐受性的贡献。 成熟CD 4 T细胞无反应性的特征-包括受损的信号转导,细胞因子产生, 增殖我们将使用散装和单细胞基因组方法来定义的机制, NR 4A家族调节幼稚和耐受性CD 4 T细胞的转录组和表观遗传谱。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JULIE ZIKHERMAN其他文献

JULIE ZIKHERMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JULIE ZIKHERMAN', 18)}}的其他基金

Regulation of CD4 T cell tolerance by the NR4A family of nuclear receptors
核受体 NR4A 家族对 CD4 T 细胞耐受性的调节
  • 批准号:
    10707222
  • 财政年份:
    2022
  • 资助金额:
    $ 60.31万
  • 项目类别:
Nuclear Receptors in B Cell Tolerance and Humoral Immune Responses
B 细胞耐受和体液免疫反应中的核受体
  • 批准号:
    10626756
  • 财政年份:
    2020
  • 资助金额:
    $ 60.31万
  • 项目类别:
Nuclear Receptors in B Cell Tolerance and Humoral Immune Responses
B 细胞耐受和体液免疫反应中的核受体
  • 批准号:
    10410354
  • 财政年份:
    2020
  • 资助金额:
    $ 60.31万
  • 项目类别:
Nuclear Receptors in B Cell Tolerance and Humoral Immune Responses
B 细胞耐受和体液免疫反应中的核受体
  • 批准号:
    10192648
  • 财政年份:
    2020
  • 资助金额:
    $ 60.31万
  • 项目类别:
Dissecting unique functions of IgM and IgD BCRs in tolerance and autoimmunity
剖析 IgM 和 IgD BCR 在耐受和自身免疫中的独特功能
  • 批准号:
    9193713
  • 财政年份:
    2016
  • 资助金额:
    $ 60.31万
  • 项目类别:
Dissecting unique functions of IgM and IgD BCRs in tolerance and autoimmunity
剖析 IgM 和 IgD BCR 在耐受和自身免疫中的独特功能
  • 批准号:
    9899730
  • 财政年份:
    2016
  • 资助金额:
    $ 60.31万
  • 项目类别:
Dissecting unique functions of IgM and IgD BCRs in tolerance and autoimmunity
剖析 IgM 和 IgD BCR 在耐受和自身免疫中的独特功能
  • 批准号:
    9479603
  • 财政年份:
    2016
  • 资助金额:
    $ 60.31万
  • 项目类别:
Titrating CD45 expression in mice to study development of T cell tolerance
滴定小鼠 CD45 表达以研究 T 细胞耐受的发展
  • 批准号:
    8098871
  • 财政年份:
    2010
  • 资助金额:
    $ 60.31万
  • 项目类别:
Titrating CD45 expression in mice to study development of T cell tolerance
滴定小鼠 CD45 表达以研究 T 细胞耐受的发展
  • 批准号:
    8701864
  • 财政年份:
    2010
  • 资助金额:
    $ 60.31万
  • 项目类别:
Titrating CD45 expression in mice to study development of T cell tolerance
滴定小鼠 CD45 表达以研究 T 细胞耐受的发展
  • 批准号:
    7952505
  • 财政年份:
    2010
  • 资助金额:
    $ 60.31万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 60.31万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 60.31万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 60.31万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 60.31万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 60.31万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 60.31万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 60.31万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 60.31万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 60.31万
  • 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
  • 批准号:
    10534864
  • 财政年份:
    2023
  • 资助金额:
    $ 60.31万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了